The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation

Graeme Barker, Euan Parnell, Boy Van Basten, Hanna Buist, David Roger Adams, Stephen John Yarwood

Research output: Contribution to journalLiterature reviewpeer-review

15 Citations (Scopus)
126 Downloads (Pure)


The cyclic 3′,5′-adenosine monophosphate (cAMP) sensor enzyme, EPAC1, is a candidate drug target in vascular endothelial cells (VECs) due to its ability to attenuate proinflammatory cytokine signalling normally associated with cardiovascular diseases (CVDs), including atherosclerosis. This is through the EPAC1-dependent induction of the suppressor of cytokine signalling gene, SOCS3, which targets inflammatory signalling proteins for ubiquitinylation and destruction by the proteosome. Given this important role for the EPAC1/SOCS3 signalling axis, we have used high throughput screening (HTS) to identify small molecule EPAC1 regulators and have recently isolated the first known non-cyclic nucleotide (NCN) EPAC1 agonist, I942. I942 therefore represents the first in class, isoform selective EPAC1 activator, with the potential to suppress pro-inflammatory cytokine signalling with a reduced risk of side effects associated with general cAMP-elevating agents that activate multiple response pathways. The development of augmented I942 analogues may therefore provide improved research tools to validate EPAC1 as a potential therapeutic target for the treatment of chronic inflammation associated with deadly CVDs
Original languageEnglish
Pages (from-to)22-37
Number of pages16
JournalJournal of Cardiovascular Disease and Development
Issue number4
Publication statusPublished - 5 Dec 2017


Dive into the research topics of 'The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation'. Together they form a unique fingerprint.

Cite this